NASDAQ:OGEN - Oragenics Stock Price, News & Analysis

$0.44
-0.01 (-2.23 %)
(As of 08/25/2019 04:00 PM ET)
Today's Range
$0.4251
Now: $0.4392
$0.48
50-Day Range
$0.36
MA: $0.44
$0.49
52-Week Range
$0.35
Now: $0.4392
$3.74
Volume786,381 shs
Average Volume1.17 million shs
Market Capitalization$20.26 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Oragenics, Inc. develops novel antibiotics against infectious diseases and treatments for oral mucositis. It is developing OG716, an antibiotic product candidate, which is in nonclinical testing for healthcare-associated infections, as well as other homolog antibiotic product candidates. The company is also developing AG013, which is in Phase II clinical trial for the treatment of oral mucositis in cancer patients. Its product candidates also comprise LPT3-04, a naturally occurring chemical agent for use in weight loss; and SMaRT Replacement Therapy, a topical treatment applied to the teeth to protect against tooth decay. Oragenics, Inc. has collaboration agreements with Intrexon Corporation and its subsidiary, Intrexon Actobiotics NV to develop AG013; a license agreement with LPThera LLC to develop LPT3-04; and a license agreement Texas A&M University System for access to new homologs of the lantibiotic MU1140 and other lantibiotics. The company was formerly known as Oragen, Inc. Oragenics, Inc. was founded in 1996 and is headquartered in Tampa, Florida.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:OGEN
CUSIPN/A
CIKN/A
Phone813-286-7900

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees6
Market Cap$20.26 million
Next Earnings Date11/12/2019 (Estimated)
OptionableNot Optionable

Receive OGEN News and Ratings via Email

Sign-up to receive the latest news and ratings for OGEN and its competitors with MarketBeat's FREE daily newsletter.


Oragenics (NASDAQ:OGEN) Frequently Asked Questions

What is Oragenics' stock symbol?

Oragenics trades on the NASDAQ under the ticker symbol "OGEN."

When is Oragenics' next earnings date?

Oragenics is scheduled to release their next quarterly earnings announcement on Tuesday, November 12th 2019. View Earnings Estimates for Oragenics.

What is the consensus analysts' recommendation for Oragenics?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Oragenics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Oragenics.

Has Oragenics been receiving favorable news coverage?

Media stories about OGEN stock have been trending positive this week, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Oragenics earned a media sentiment score of 2.5 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 6.0 out of 10, meaning that recent news coverage is somewhat likely to have an effect on the stock's share price in the next few days. View News Stories for Oragenics.

Who are some of Oragenics' key competitors?

What other stocks do shareholders of Oragenics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Oragenics investors own include JD.Com (JD), Jaguar Health (JAGX), iRobot (IRBT), Intel (INTC), Gilead Sciences (GILD), Auris Medical (EARS), Electronic Arts (EA), Activision Blizzard (ATVI), Advanced Micro Devices (AMD) and Align Technology (ALGN).

Who are Oragenics' key executives?

Oragenics' management team includes the folowing people:
  • Dr. Alan F. Joslyn, Pres, CEO & Director (Age 60)
  • Mr. Michael O. Sullivan CPA, CFO, Sec. & Treasurer (Age 63)
  • Dr. Martin Handfield, Sr. VP of Discovery Research (Age 48)
  • Dr. Raman Bedi, Chairman of International Scientific Advisory Board and Sr. Consultant

How do I buy shares of Oragenics?

Shares of OGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Oragenics' stock price today?

One share of OGEN stock can currently be purchased for approximately $0.4392.

How big of a company is Oragenics?

Oragenics has a market capitalization of $20.26 million. Oragenics employs 6 workers across the globe.View Additional Information About Oragenics.

What is Oragenics' official website?

The official website for Oragenics is http://www.oragenics.com/.

How can I contact Oragenics?

The company can be reached via phone at 813-286-7900.


MarketBeat Community Rating for Oragenics (NASDAQ OGEN)

Community Ranking:  1.8 out of 5 (star)
Outperform Votes:  8 (Vote Outperform)
Underperform Votes:  14 (Vote Underperform)
Total Votes:  22
MarketBeat's community ratings are surveys of what our community members think about Oragenics and other stocks. Vote "Outperform" if you believe OGEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OGEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/25/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel